Pere Domingo, Domingo P, Domingo Pedrol P, Pedrol PD, Domingo PP

Pere Domingo; Pere Domingo Pedrol; Pedrol PD; Domingo PP; Domingo-Pedrol P

https://orcid.org/0000-0003-1138-5770

Biography

Dr. Pere Domingo is currently Senior Consultant and HIV/AIDS Program Director at the Infectious Diseases Unit of the Hospital de la Santa Creu i Sant Pau. He graduated with honours in the University of Barcelona in 1980 and achieved his PhD degree in the Autonomous University of Barcelona in 1993 (Magna cum laude). He has been devoted to infectious diseases and HIV infection since 1989. He has served as Head of the Infectious Diseases Department at Hospitals Universitaris Arnau de Vilanova & Santa María at Lleida, Spain in the years 2016-2017. He has been Associate Professor of Medicine at the Medicine School (Autonomous University of Barcelona) from 1994 to 2016. He was also Professor of Medicine at the University of Lleida in the years 2016 and 2017.He has authored or co-authored more than 700 scientific papers and more than 100 book chapters. He has been the speaker in more than 500 meetings or congresses and is currently reviewer for more than 60 international journals (including Science, NEJM, the Lancet, Lancet HIV, Lancet Infect Dis, E-Clinical Medicine, Clin Infect Dis, BMC Infect Dis, PLoS One,…), national (ISC III and AQUAS), international agencies (British HIV Association, ANRS, Swiss Foundation for Science, South African Medical Council, …) , and international meetings and conferences. He is now member of 12 Editorial Boards of medical journals, including Biomed Res Int and Clin Infect Dis. He has been PI in more than 200 clinical trials. Dr. Domingo is an expert member of the Spanish Medicines Agency and of the European Medicines Agency. His main research interests are antiretroviral therapy and its complications, especially fat redistribution syndromes, metabolic alterations, insulin resistance, cardiovascular risk, and early senescence, but also meningococcal disease and bacterial meningitis in adults. Dr. Domingo is the past President of the Spanish AIDS study group (2011-2013), of the Spanish Society of Infectious Diseases and Clinical Microbiology and past Coordinator of the Clinical Medicine and Epidemiology area for the Spanish National Evaluation Agency (ANEP) for the years 2014-2017.

Personal information

Other IDs

- SciProfiles: 1004051 (https://sciprofiles.com/profile/1004051)
- Loop profile: 930858 (http://loop.frontiersin.org/people/930858/overview?referrer=orcid_profile)

Countries

- Spain

Activities

Employments (1)

- **Hospital de la Santa Creu i Sant Pau**
  Organization address: Barcelona, Catalunya, ES
  Start date: 1981-04-01
  End date: 2015-12-31
  Role title: Senior Consultant
  Department: Infectious Diseases

Education and qualifications (1)

- **University of Barcelona**
  Organization address: Barcelona, ES
  Start date: 1974-01-01
  End date: 1980-06-10
  Role title: Medical Doctor
  Department: Medicine
  Type: education

Works (39)

- **Proof-of-Concept Phase 2a Trial of VH4524184: An Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile**
  Publication date: 2026-10-28
  Journal: Clinical Infectious Diseases
  Type: journal-article
  URL: https://doi.org/10.1093/cid/ciag357
  doi: 10.1093/cid/ciag357 (https://doi.org/10.1093/cid/ciag357)
- **Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL)**
  Publication date: 2026-10-06
  Journal: Journal of Antimicrobial Chemotherapy
  Type: journal-article
  URL: https://doi.org/10.1093/jac/dkag336
  doi: 10.1093/jac/dkag336 (https://doi.org/10.1093/jac/dkag336)

- **Beyond Lipid Lowering: A Narrative Review and Expert Perspective on Precision Cardiovascular Prevention in People with HIV After REPRIEVE**
  Publication date: 2026-08-29
  Journal: Biomolecules
  Type: journal-article
  URL: https://doi.org/10.3390/biom16091254
  doi: 10.3390/biom16091254 (https://doi.org/10.3390/biom16091254)
- **Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial**
  Publication date: 2026-04-27
  Journal: Nature Communications
  Type: journal-article
  URL: https://doi.org/10.1038/s41467-026-72458-w
  doi: 10.1038/s41467-026-72458-w (https://doi.org/10.1038/s41467-026-72458-w)
- **Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)**
  Publication date: 2026-03-17
  Journal: Clinical Infectious Diseases
  Type: journal-article
  URL: https://doi.org/10.1093/cid/ciaf407
  doi: 10.1093/cid/ciaf407 (https://doi.org/10.1093/cid/ciaf407)
- **Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial**
  Publication date: 2026-03-04
  Journal: Nature Communications
  Type: journal-article
  URL: https://doi.org/10.1038/s41467-026-69846-7
  doi: 10.1038/s41467-026-69846-7 (https://doi.org/10.1038/s41467-026-69846-7)
- **Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort Collaboration**
  Publication date: 2025-12-16
  Journal: Cancers
  Type: journal-article
  URL: https://doi.org/10.3390/cancers17244000
  doi: 10.3390/cancers17244000 (https://doi.org/10.3390/cancers17244000)
- **Una enfermedad sin nombre. De Tucídices al ADN: Repensando la peste de Atenas.**
  Publication date: 2025-12-15
  Journal: Índice Histórico Español
  Type: journal-article

URL: https://doi.org/10.1344/IHE2025.138.8
doi: 10.1344/IHE2025.138.8 (https://doi.org/10.1344/IHE2025.138.8)

- **48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial**
  Publication date: 2025-08-01
  Journal: Journal of Antimicrobial Chemotherapy
  Type: journal-article
  URL: https://doi.org/10.1093/jac/dkaf192
  doi: 10.1093/jac/dkaf192 (https://doi.org/10.1093/jac/dkaf192)
- **Dolutegravir Restores Gut Microbiota in Late-stage HIV-1 Unlike Darunavir: An Open-Label, Randomized Clinical Trial**
  Publication date: 2025-07-21
  Type: preprint
  URL: https://doi.org/10.21203/rs.3.rs-6782809/v1
  doi: 10.21203/rs.3.rs-6782809/v1 (https://doi.org/10.21203/rs.3.rs-6782809/v1)
- **Lipodystrophy in HIV: Evolving Challenges and Unresolved Questions**
  Publication date: 2025-07-08
  Journal: International Journal of Molecular Sciences
  Type: journal-article
  URL: https://doi.org/10.3390/ijms26146546
  doi: 10.3390/ijms26146546 (https://doi.org/10.3390/ijms26146546)
- **Blood CD45+/CD3+ lymphocyte-released extracellular vesicles and mortality in hospitalized patients with coronavirus disease 2019**
  Publication date: 2025-02
  Journal: European Journal of Clinical Investigation
  Type: journal-article
  URL: https://doi.org/10.1111/eci.14354
  doi: 10.1111/eci.14354 (https://doi.org/10.1111/eci.14354)
- **Lung Nodules and Masses in non-HIV Immunocompromised Patients: A Clinical-Imaging Algorithmic Approach**
  Publication date: 2024-11
  Journal: CHEST
  Type: journal-article
  URL: https://doi.org/10.1016/j.chest.2024.10.054
  doi: 10.1016/j.chest.2024.10.054 (https://doi.org/10.1016/j.chest.2024.10.054)
- **CD66b+/CD68+ circulating extracellular vesicles, lactate dehydrogenase and neutrophil-to-lymphocyte ratio can differentiate coronavirus disease 2019 severity during and after infection**
  Publication date: 2024-07

Journal: Journal of Extracellular Vesicles
Type: journal-article
URL: https://doi.org/10.1002/jev2.12456
doi: 10.1002/jev2.12456 (https://doi.org/10.1002/jev2.12456)

- **Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine**
  Publication date: 2024-05-02
  Journal: Journal of Antimicrobial Chemotherapy
  Type: journal-article
  URL: https://doi.org/10.1093/jac/dkae083
  doi: 10.1093/jac/dkae083 (https://doi.org/10.1093/jac/dkae083)
- **Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998–2020**
  Publication date: 2024-03-28
  Journal: Open Forum Infectious Diseases
  Type: journal-article
  URL: https://doi.org/10.1093/ofid/ofae132
  doi: 10.1093/ofid/ofae132 (https://doi.org/10.1093/ofid/ofae132)
- **Mpox: Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide Study**
  Publication date: 2023-11-03
  Journal: Microorganisms
  Type: journal-article
  URL: https://doi.org/10.3390/microorganisms11112701
  doi: 10.3390/microorganisms11112701 (https://doi.org/10.3390/microorganisms11112701)
- **A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes**
  Publication date: 2023-11-01
  Journal: Open Forum Infectious Diseases
  Type: journal-article
  URL: https://doi.org/10.1093/ofid/ofad542
  doi: 10.1093/ofid/ofad542 (https://doi.org/10.1093/ofid/ofad542)
- **Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide**
  Publication date: 2023-10-03
  Journal: The Journal of Infectious Diseases
  Type: journal-article
  URL: https://doi.org/10.1093/infdis/jiad304

doi: 10.1093/infdis/jiad304 (https://doi.org/10.1093/infdis/jiad304)

- **Monkeypox (mpox): Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide Study**
  Publication date: 2023-09-06
  Type: preprint
  URL: https://doi.org/10.20944/preprints202309.0225.v1
  doi: 10.20944/preprints202309.0225.v1 (https://doi.org/10.20944/preprints202309.0225.v1)
- **Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir**
  Publication date: 2023-09-05
  Journal: Journal of Antimicrobial Chemotherapy
  Type: journal-article
  URL: https://doi.org/10.1093/jac/dkad247
  doi: 10.1093/jac/dkad247 (https://doi.org/10.1093/jac/dkad247)
- **Acute Bacterial Meningitis in Healthy Adult Patients: A Prospective Cohort Study**
  Publication date: 2023-05-23
  Journal: Journal of Clinical Medicine
  Type: journal-article
  URL: https://doi.org/10.3390/jcm12113624
  doi: 10.3390/jcm12113624 (https://doi.org/10.3390/jcm12113624)
- **Adipose tissue aging partially accounts for fat alterations in HIV lipodystrophy**
  Publication date: 2022-12-31
  Journal: Adipocyte
  Type: journal-article
  URL: https://doi.org/10.1080/21623945.2022.2042962
  doi: 10.1080/21623945.2022.2042962 (https://doi.org/10.1080/21623945.2022.2042962)
- **Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019**
  Publication date: 2022-08
  Journal: HIV Medicine
  Type: journal-article
  URL: https://doi.org/10.1111/hiv.13229
  doi: 10.1111/hiv.13229 (https://doi.org/10.1111/hiv.13229)
- **Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study**
  Publication date: 2022-07-28
  Journal: Journal of Antimicrobial Chemotherapy
  Type: journal-article
  URL: https://doi.org/10.1093/jac/dkac177

doi: 10.1093/jac/dkac177 (https://doi.org/10.1093/jac/dkac177)

- **Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation**
  Publication date: 2022-07-22
  Journal: International Journal of Molecular Sciences
  Type: journal-article
  URL: https://doi.org/10.3390/ijms23158071
  doi: 10.3390/ijms23158071 (https://doi.org/10.3390/ijms23158071)
- **Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study**
  Publication date: 2022-06-29
  Journal: Journal of Antimicrobial Chemotherapy
  Type: journal-article
  URL: https://doi.org/10.1093/jac/dkac117
  doi: 10.1093/jac/dkac117 (https://doi.org/10.1093/jac/dkac117)
- **Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)**
  Publication date: 2022-03-01
  Journal: Open Forum Infectious Diseases
  Type: journal-article
  URL: https://doi.org/10.1093/ofid/ofab595
  doi: 10.1093/ofid/ofab595 (https://doi.org/10.1093/ofid/ofab595)
- **Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy**
  Publication date: 2022-02-17
  Journal: International Journal of Molecular Sciences
  Type: journal-article
  URL: https://doi.org/10.3390/ijms23042202
  doi: 10.3390/ijms23042202 (https://doi.org/10.3390/ijms23042202)
- **Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy**
  Publication date: 2022-01-22
  Journal: Journal of Clinical Medicine
  Type: journal-article
  URL: https://doi.org/10.3390/jcm11030549
  doi: 10.3390/jcm11030549 (https://doi.org/10.3390/jcm11030549)

- **Alpha variant SARS-CoV-2 infection: How it all starts**
  Publication date: 2021-12
  Journal: eBioMedicine
  Type: journal-article
  URL: https://doi.org/10.1016/j.ebiom.2021.103703
  doi: 10.1016/j.ebiom.2021.103703 (https://doi.org/10.1016/j.ebiom.2021.103703)
- **Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19**
  Publication date: 2021-10
  Journal: Diagnostics
  Type: journal-article
  URL: https://www.mdpi.com/2075-4418/11/11/1998
  doi: 10.3390/diagnostics11111998 (https://doi.org/10.3390/diagnostics11111998)
- **Standardized Comparison of Cardiovascular Risk Factors Prevalence in Spanish Women and Men Living with HIV and in the General Population**
  Publication date: 2021-10
  Journal: Journal of Personalized Medicine
  Type: journal-article
  URL: https://www.mdpi.com/2075-4426/11/11/1085
  doi: 10.3390/jpm11111085 (https://doi.org/10.3390/jpm11111085)
- **Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV**
  Publication date: 2021-08-12
  Journal: Journal of Antimicrobial Chemotherapy
  Type: journal-article
  URL: https://doi.org/10.1093/jac/dkab158
  doi: 10.1093/jac/dkab158 (https://doi.org/10.1093/jac/dkab158)
- **Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)**
  Publication date: 2021-06-13
  Journal: Expert Opinion on Pharmacotherapy
  Type: journal-article
  URL: https://doi.org/10.1080/14656566.2021.1887140
  doi: 10.1080/14656566.2021.1887140 (https://doi.org/10.1080/14656566.2021.1887140)
- **The pharmacological management of cardiovascular disease in people living with HIV (PLWH)**
  Publication date: 2021-04-13
  Journal: Expert Opinion on Pharmacotherapy
  Type: journal-article

URL: https://doi.org/10.1080/14656566.2020.1856075
doi: 10.1080/14656566.2020.1856075 (https://doi.org/10.1080/14656566.2020.1856075)

- **Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping**
  Publication date: 2020-12-01
  Journal: Journal of Antimicrobial Chemotherapy
  Type: journal-article
  URL: https://doi.org/10.1093/jac/dkaa349
  doi: 10.1093/jac/dkaa349 (https://doi.org/10.1093/jac/dkaa349)
- **Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease**
  Publication date: 2020-11-01
  Journal: Journal of Antimicrobial Chemotherapy
  Type: journal-article
  URL: https://doi.org/10.1093/jac/dkaa292
  doi: 10.1093/jac/dkaa292 (https://doi.org/10.1093/jac/dkaa292)
- **The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19)**
  Publication date: 2020-08
  Journal: EBioMedicine
  Type: journal-article
  URL: https://doi.org/10.1016/j.ebiom.2020.102887
  doi: 10.1016/j.ebiom.2020.102887 (https://doi.org/10.1016/j.ebiom.2020.102887)

Peer review (19 reviews for 12 publications/grants)

- **Archives of medical research.** (1)
- **BMC infectious diseases** (1)
- **Clinical infectious diseases.** (4)
- **EClinicalMedicine.** (1)
- **International journal of infectious diseases.** (1)
- **International journal of obesity.** (1)
- **Journal of infection and public health.** (1)
- **Journal of medical microbiology.** (1)
- **Open forum infectious diseases.** (3)
- **The Lancet. Diabetes & endocrinology.** (2)

- **The lancet. HIV.** (1)
- **iScience.** (2)